Allergy and Immunology, Allergy · Westerville, OH
NPI
1861499741
Since 2005
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
477 Cooper Rd Ste 480
Westerville, OH, 43081
Phone (614) 823-7135
Groups this clinician bills Medicare through
Medicare paid, 2024
$93K
9,462 services
Medicare patients, 2024
380
Average age 72
Drug cost, 2024
$2.4M
1,096 prescriptions
Company payments, 2025
$2,096
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mehmet Basaran was code 95004 (test - miscellaneous), 3,607 times for 60 patients. In total Mehmet Basaran billed 9,462 services in 28 codes, and Medicare paid $93K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 3,607 | 60 | $2.49 | $8,978 |
| 95165 Treatment - Miscellaneous | Office | 1,348 | 173 | $9.07 | $12K |
| 95115 Treatment - Miscellaneous | Office | 570 | 77 | $6.06 | $3,454 |
| 95024 Test - Miscellaneous | Office | 478 | 49 | $5.64 | $2,696 |
| 95117 Treatment - Miscellaneous | Office | 133 | 28 | $7.15 | $951 |
| 94375 Pulmonary Function Testing | Office | 87 | 58 | $25.33 | $2,204 |
| 99213 Office E&M - Established | Office | 85 | 70 | $55.34 | $4,704 |
| 95012 Pulmonary | Office | 80 | 53 | $12.07 | $965 |
| 99214 Office E&M - Established | Office | 58 | 41 | $76.53 | $4,439 |
| 99203 Office E&M - New | Office | 56 | 56 | $75.54 | $4,230 |
| 99212 Office E&M - Established | Office | 16 | 15 | $35.12 | $562 |
By year: 2022 $47K for 6,641 services; 2023 $66K for 7,769 services; 2024 $93K for 9,462 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mehmet Basaran prescribed most often to Medicare patients was Montelukast Sodium, with 151 prescriptions and refills. In total Mehmet Basaran wrote 1,096 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 151 | 382 | 44 | $1,605 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 85 | 93 | 40 | $2,054 |
| Breo Ellipta Fluticasone/Vilanterol | 81 | 105 | 18 | $41K |
| Diphenhydramine Hcl Generic | 77 | 77 | Under 11 | $5,101 |
| Fluticasone Propionate Generic | 75 | 163 | 27 | $1,246 |
| Levocetirizine Dihydrochloride Generic | 71 | 183 | 21 | $1,499 |
| Arnuity Ellipta Fluticasone Furoate | 69 | 85 | 13 | $17K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 57 | 85 | 18 | $5,335 |
| Azelastine Hcl Generic | 41 | 76 | 18 | $930 |
| Ipratropium Bromide Generic | 38 | 46 | Under 11 | $1,020 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 25 | 45 | 11 | $2,940 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 20 | 26 | Under 11 | $16K |
| Prednisone Generic | 17 | 17 | 17 | $28.08 |
| Famotidine Generic | 15 | 33 | Under 11 | $261 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 15 | 17 | Under 11 | $10K |
Brand drugs: 442 claims; generic drugs: 654 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mehmet Basaran $2,096 ($2,096 in general payments such as food, travel and fees) from 22 companies. The largest payer was Genzyme Corporation with $356.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 20 | $356 |
| CSL Behring CSL.AX | 13 | $265 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $258 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $191 |
| Amgen Inc. AMGN | 20 | $183 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 7 | $136 |
| Pfizer Inc. PFE | 6 | $134 |
| Grifols USA, LLC | 6 | $94.49 |
| Octapharma USA, Inc. | 3 | $61.5 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $55.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.